MSTN and Duchenne muscular dystrophy: Supporting this hypothesis, anti-myostatin antibodies improved muscle performance in a mouse model of Duchenne muscular dystrophy and prevented skeletal muscle alterations in a Huntington’s disease mouse model [149]; moreover, the administration of follistatin, a natural antagonist of myostatin, improved the severity of SMA in mice [150].